- Asymptomatic or mild symptoms; intervention not indicated
- Symptomatic; topical interventions indicated (e.g., antibiotics); limiting instrumental ADLs
- Limiting self-care ADLs
Management
- Encourage patient to report any eye symptom immediately
- Obtain ophthalmology referral
- Anticipate ipilimumab holds for any Grade 2 AE; resume when returns to G0 or 1; permanently discontinue for any G3 AE, persistent G2 AE lasting ≥6 weeks, or inability to reduce corticosteroid dosage to 7.5 mg/d prednisone or equivalent
© 2024 The Melanoma Hub, Terranova Medica, LLC, and Integrita Foundation, LLC. All rights reserved.